Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Inhibitory guanosine triphosphate-binding protein-mediated regulation of vasopressin action in isolated single medullary tubules of mouse kidney.
K Takaichi, K Kurokawa
K Takaichi, K Kurokawa
Published October 1, 1988
Citation Information: J Clin Invest. 1988;82(4):1437-1444. https://doi.org/10.1172/JCI113749.
View: Text | PDF
Research Article

Inhibitory guanosine triphosphate-binding protein-mediated regulation of vasopressin action in isolated single medullary tubules of mouse kidney.

  • Text
  • PDF
Abstract

Vasopressin (AVP) plays a key role in maximal urine concentration by stimulating NaCl reabsorption in the medullary thick ascending limbs of Henle (MAL) and by increasing water permeability in the medullary collecting tubules (MCT). These effects of AVP in MAL and MCT are mediated by cAMP. Alpha 2-adrenergic stimulation in MCT, and high ambient Ca2+ and PGE2 in MAL inhibit AVP-dependent cAMP production and thereby modulate urine concentration. The present study was undertaken to clarify the mechanisms underlying the inhibition of AVP-dependent cAMP production by these agents using microdissected mouse MAL and MCT. Preincubation of MCT and MAL with 1 microgram/ml pertussis toxin for 3 and 6 h, respectively, resulted in ADP-ribosylation of an approximately 41-kD protein, which was presumably an alpha subunit of the inhibitory GTP-binding protein Gi. Epinephrine, 10(-6) M, via alpha 2-adrenergic stimulation, inhibited AVP-dependent cAMP production in MCT. Preincubation of MCT for 3 h with pertussis toxin abolished the inhibition of AVP-dependent cAMP production by epinephrine. High ambient Ca2+ and PGE2 both inhibited AVP-dependent cAMP production in MAL. Preincubation of MAL for 6 h with pertussis toxin abolished the inhibition by high ambient Ca2+ and attenuated the inhibition by PGE2. Preincubation of MCT or MAL with pertussis toxin for 1 h was ineffective in ADP-ribosylation and did not modify the inhibition of AVP-dependent cAMP production by these agents in both nephron segments. Our data suggest that the inhibition of AVP-dependent cAMP production by alpha 2-adrenergic stimulation in MCT, and by high ambient Ca2+ and adrenergic stimulation in MCT, and by high ambient Ca2+ and PGE2 in MAL, is mediated, at least in part, through activation of Gi.

Authors

K Takaichi, K Kurokawa

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts